Article
Cardiac & Cardiovascular Systems
Jan Steffel, Christian T. Ruff, Ophelia Yin, Eugene Braunwald, Jeong-Gun Park, Sabina A. Murphy, Stuart Connolly, Elliott M. Antman, Robert P. Giugliano
Summary: In the ENGAGE AF-TIMI 48 trial, the lower dose edoxaban regimen (LDER) showed a reduced primary net clinical outcome compared to the higher dose edoxaban regimen (HDER), while the secondary and tertiary net clinical outcomes were similar between the two dosing regimens.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2021)
Article
Pharmacology & Pharmacy
Shin-Yi Lin, Ching-Hua Kuo, Li-Ting Ho, Yen-Bin Liu, Chih-Fen Huang, Sung-Chun Tang, Jiann-Shing Jeng
Summary: The study identified factors associated with increased or decreased edoxaban exposure. Higher trough concentrations were associated with higher creatinine clearance and the use of the 30 mg regimen, while higher peak concentrations were associated with an off-label overdosing regimen.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Clinical Neurology
Yutao Guo, Agnieszka Kotalczyk, Jacopo F. Imberti, Yutang Wang, Gregory Y. H. Lip
Summary: This study demonstrates that in very elderly atrial fibrillation patients in China, the use of oral anticoagulants is an independent predictor for lower risk of composite outcomes and all-cause death, highlighting the importance of not withholding oral anticoagulant therapy based on advanced age.
INTERNATIONAL JOURNAL OF STROKE
(2022)
Article
Medicine, General & Internal
Shintaro Akashi, Mitsutoshi Oguri, Eiichiro Ikeno, Mamoru Manita, Junki Taura, Saori Watanabe, Takuya Hayashi, Masaharu Akao, Ken Okumura, Masahiro Akishita, Takeshi Yamashita
Summary: This study aimed to compare the effects of very-low-dose edoxaban with placebo in frail elderly patients with atrial fibrillation. The results showed that edoxaban was associated with a reduced incidence of stroke or systemic embolism, regardless of frailty status.
Article
Pharmacology & Pharmacy
Shin-Yi Lin, Sung-Chun Tang, Ching-Hua Kuo, Li-Ting Ho, Yen-Bin Liu, Yu-Fong Peng, Li-Kai Tsai, Chih-Fen Huang, Jiann-Shing Jeng
Summary: This study reports on the association between direct oral anticoagulant (DOAC) concentration and clinical outcomes in Asian patients with atrial fibrillation (AF). The proportion of DOAC concentrations falling outside the expected range was higher than reported in clinical trials. Low trough concentration was associated with increased risk of systemic thromboembolism (SSE), while high trough concentration was associated with major bleeding. Measurement of trough DOAC concentration should be considered for patients at risk of concentration deviations.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Medicine, General & Internal
Yi-Hsin Chan, Tze-Fan Chao, Shao-Wei Chen, Hsin-Fu Lee, Wei-Min Chen, Pei-Ru Li, Yung-Hsin Yeh, Chi-Tai Kuo, Lai-Chu See, Gregory Y. H. Lip
Summary: This study suggests a higher risk of incident ILD associated with the use of FXa inhibitors in patients with NVAF. Physicians should be vigilant in monitoring potential adverse lung outcomes related to the use of these drugs.
Article
Pharmacology & Pharmacy
Sylvie Perreault, Alice Dragomir, Robert Cote, Aurelie Lenglet, Simon de Denus, Marc Dorais, Brian White-Guay, James Brophy, Mireille E. Schnitzer, Marie-Pierre Dube, Jean-Claude Tardif
Summary: This study compares the effectiveness and safety of different doses of direct oral anticoagulants (DOACs) with warfarin or other DOACs for patients with atrial fibrillation (AF). The results show that low-dose dabigatran has better effectiveness but worse safety compared to warfarin, while low-dose apixaban has better safety than warfarin.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Eue-Keun Choi, Wei-Shiang Lin, Gyo-Seung Hwang, Paulus Kirchhof, Raffaele De Caterina, Cathy Chen, Martin Unverdorben, Chun-Chieh Wang, Young-Hoon Kim
Summary: Edoxaban has been approved for stroke prevention in nonvalvular atrial fibrillation (AF) patients in several countries. The Global ETNA study reported 1-year clinical events in AF patients receiving edoxaban in South Korea and Taiwan, showing low event rates for bleeding, strokes, and deaths, supporting the safety and effectiveness of edoxaban in this population.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Vito A. Mannacio, Luigi Mannacio, Anita Antignano, Ciro Mauro, Pasquale Mastroroberto, Francesco Musumeci, Carlo Zebele, Gabriele Iannelli
Summary: NOACs are more effective than warfarin in preventing thromboembolic events and safer in reducing major bleeding events in patients who develop AF after bioprosthetic AVR.
ANNALS OF THORACIC SURGERY
(2022)
Article
Hematology
Pavel Olivera, Cesar Velasquez-Escandon, Desiree Campoy, Katia Flores, Tania Canals, Erik Johansson, Maria Jose Herranz, Laia Martinez, Juan Jose Cerezo-Manchado, Ramon Salinas
Summary: During the first wave of the SARS-CoV-2 pandemic, anticoagulation therapy for hospitalized AF patients was simplified to LMWH followed by oral anticoagulation due to drug-drug interactions. However, different oral anticoagulants have varying risks. This study found that edoxaban and LMWH followed by oral anticoagulation showed similar therapeutic effects and complications in AF patients, but edoxaban led to shorter hospital stays.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
(2023)
Article
Cardiac & Cardiovascular Systems
Tze-Fan Chao, Chern-En Chiang, Yi-Hsin Chan, Jo-Nan Liao, Tzeng-Ji Chen, Gregory Y. H. Lip, Shih-Ann Chen
Summary: The study investigated the effectiveness and safety of oral anticoagulation in high-risk, very elderly patients, finding that NOACs were associated with a lower risk of composite endpoint compared to warfarin or non-OACs, while warfarin had a similar or even higher risk of composite clinical outcomes compared to non-OACs.
Article
Multidisciplinary Sciences
Sylvie Perreault, Robert Cote, Alice Dragomir, Brian White-Guay, Aurelie Lenglet, Marc Dorais
Summary: There was no significant difference in the effectiveness or safety outcome between low-dose and standard-dose rivaroxaban in patients with atrial fibrillation. However, low-dose apixaban was associated with a greater risk of stroke/systemic embolism and death without a reduction in bleeding rates.
Article
Cardiac & Cardiovascular Systems
Ashwin S. Nathan, Lin Yang, Zhi Geng, Elias J. Dayoub, Sameed Ahmed M. Khatana, Paul N. Fiorilli, Howard C. Herrmann, Wilson Y. Szeto, Pavan Atluri, Michael A. Acker, Nimesh D. Desai, David S. Frankel, Francis E. Marchlinski, Alexander C. Fanaroff, Jay Giri, Peter W. Groeneveld
Summary: Between 2014 and 2018, the use of vitamin K antagonists decreased while the use of direct oral anticoagulants increased among atrial fibrillation patients undergoing different types of mitral valve repair surgeries. However, around 30% of patients did not receive any anticoagulant treatment within 90 days of discharge.
AMERICAN HEART JOURNAL
(2021)
Letter
Hematology
Christina Koehler, Luise Tittl, Sandra Marten, Christiane Naue, Marianne Spindler, Laura Stannek, Kristina Fache, Jan Beyer-Westendorf
Summary: This study investigated the clinical effectiveness and safety of edoxaban in atrial fibrillation patients. The results showed that edoxaban was effective in preventing stroke and had a comparable safety profile to previous findings. Non-thrombotic cardiovascular events and infectious diseases were the leading causes of death, while fatal stroke and fatal bleeding were rare.
THROMBOSIS RESEARCH
(2022)
Review
Pharmacology & Pharmacy
Mohammed M. Alsultan, Abdullah K. Alahmari, Mansour A. Mahmoud, Ziyad S. Almalki, Wafa Alzlaiq, Faisal Alqarni, Fahad Alsultan, Nehad Jaser Ahmed, Ahmed O. Alenazi, Lucas Scharf, Jeff Jianfei Guo
Summary: Our findings from an updated meta-analysis of real-world studies demonstrated that edoxaban outperformed warfarin in terms of major bleeding and ischemic stroke in patients with nonvalvular atrial fibrillation.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Takeshi Mikami, Kagami Hirabayashi, Keisuke Okawa, Tetsuo Betsuyaku, Saori Watanabe, Yuki Imamura, Kimihiko Tanizawa, Takuya Hayashi, Masaharu Akao, Takeshi Yamashita, Ken Okumura
Summary: This study found that baseline hemoglobin levels, prothrombin time, and creatinine clearance may predict major bleeding events during treatment with edoxaban 15mg in elderly patients with nonvalvular atrial fibrillation and high bleeding risk.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2022)
Article
Cardiac & Cardiovascular Systems
Ken Okumura, Gregory Y. H. Lip, Masaharu Akao, Kimihiko Tanizawa, Masayuki Fukuzawae, Kenji Abe, Masahiro Akishita, Takeshi Yamashita
AMERICAN HEART JOURNAL
(2017)